DK1480669T3 - Anvendelse af splejsningsvariant MGF af den insulinlignende vækstfaktor I til forebyggelse af myokardieskader - Google Patents

Anvendelse af splejsningsvariant MGF af den insulinlignende vækstfaktor I til forebyggelse af myokardieskader

Info

Publication number
DK1480669T3
DK1480669T3 DK03737378.4T DK03737378T DK1480669T3 DK 1480669 T3 DK1480669 T3 DK 1480669T3 DK 03737378 T DK03737378 T DK 03737378T DK 1480669 T3 DK1480669 T3 DK 1480669T3
Authority
DK
Denmark
Prior art keywords
mgf
insulin
growth factor
splice variant
myocardial injury
Prior art date
Application number
DK03737378.4T
Other languages
Danish (da)
English (en)
Inventor
Geoffrey Goldspink
Paul Goldspink
Original Assignee
Univ London
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London, Univ Illinois filed Critical Univ London
Application granted granted Critical
Publication of DK1480669T3 publication Critical patent/DK1480669T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03737378.4T 2002-02-07 2003-02-06 Anvendelse af splejsningsvariant MGF af den insulinlignende vækstfaktor I til forebyggelse af myokardieskader DK1480669T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202906.4A GB0202906D0 (en) 2002-02-07 2002-02-07 Prevention of myocardial damage
PCT/GB2003/000537 WO2003066082A1 (en) 2002-02-07 2003-02-06 Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage

Publications (1)

Publication Number Publication Date
DK1480669T3 true DK1480669T3 (da) 2013-05-06

Family

ID=9930632

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03737378.4T DK1480669T3 (da) 2002-02-07 2003-02-06 Anvendelse af splejsningsvariant MGF af den insulinlignende vækstfaktor I til forebyggelse af myokardieskader

Country Status (9)

Country Link
US (4) US20050048028A1 (cg-RX-API-DMAC7.html)
EP (1) EP1480669B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516997A (cg-RX-API-DMAC7.html)
AU (1) AU2003244511A1 (cg-RX-API-DMAC7.html)
DK (1) DK1480669T3 (cg-RX-API-DMAC7.html)
ES (1) ES2432082T3 (cg-RX-API-DMAC7.html)
GB (1) GB0202906D0 (cg-RX-API-DMAC7.html)
PT (1) PT1480669E (cg-RX-API-DMAC7.html)
WO (1) WO2003066082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
CA2601227A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
WO2009012443A1 (en) * 2007-07-18 2009-01-22 The Board Of Trustees Of The University Of Illinois Nanoparticles for the elution of growth factors for recovery and regeneration of organs
CN101891812B (zh) * 2010-07-09 2012-10-17 山西大学 力生长因子多肽及其制备方法和用途
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460147C2 (de) 1974-12-19 1983-05-05 Ibm Deutschland Gmbh, 7000 Stuttgart Anordnung zur Dekomprimierung komprimierter Information für aus schwarzen und weißen Bereichen zusammengesetze darzustellende Zeichen
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4963665A (en) 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
DK0437563T3 (da) 1989-08-07 1995-05-29 Debio Rech Pharma Sa Bioligiske aktive lægemiddelpolymerderivater
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9101341D0 (sv) 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2123685C (en) 1991-11-25 2003-10-07 Hans-Arne Hansson Medicament for promoting growth of mammalian nerve
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
PT1075282E (pt) 1998-04-28 2005-09-30 Applied Research Systems Conjugados analogos de peg-lhrh
GB9926968D0 (en) 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) * 2000-05-10 2000-06-28 Univ London Repair of nerve damage
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
GB0203552D0 (en) 2002-02-14 2002-04-03 Beaumont Nicholas J Peptide growth factor
WO2006097682A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use

Also Published As

Publication number Publication date
US9919031B2 (en) 2018-03-20
JP2005516997A (ja) 2005-06-09
US20130210723A1 (en) 2013-08-15
EP1480669A1 (en) 2004-12-01
US20080039390A1 (en) 2008-02-14
AU2003244511A1 (en) 2003-09-02
EP1480669B1 (en) 2013-01-23
PT1480669E (pt) 2013-05-22
WO2003066082A1 (en) 2003-08-14
US20180271942A1 (en) 2018-09-27
GB0202906D0 (en) 2002-03-27
US20050048028A1 (en) 2005-03-03
ES2432082T3 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
DK1505998T3 (da) Forbedret anvendelse af hop-syrer som antimikrobielle midler
ID30176A (id) Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DE60317564D1 (de) Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
NO20054310D0 (no) Polyetylenglykolbundede GLP-1-forbindelser
FR2842416B1 (fr) Composition cosmetique
DE60319353D1 (de) Verzweigte gefässstütze
PL1636190T3 (pl) Trwały kryształ związku 4-oksochinoliny
ATE392508T1 (de) Kunstrasen
DE60313015D1 (de) Künstlicher satellit
DK1274427T3 (da) Formulering af substituerede benzimidazoler
DK1248608T3 (da) Diacerein til anvendelse i behandling af psoriasis
ITMI992040A0 (it) Composizione di fibra di vetro
NO990937D0 (no) Kunstig rev
DE60327731D1 (de) Fasernhaltige kosmetische Zusammensetzung
EP1483963A4 (en) FALSE BAIT
DE60333439D1 (de) Herstellung von olefinen
DK1351697T3 (da) Lægemiddel til fremme af regenerationen af væv
NO20034245D0 (no) Aromataseinhibering for å öke kunstig befruktning
AU2003244511A1 (en) Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage
ITCR20020014A0 (it) Piscina fuori terra tracimante
DE69940563D1 (de) Wachstum von aluminium-einkristallen
FR2847420B1 (fr) Debroussailleuse de type perfectionne
AT500197B1 (de) Kreiselschwader
NO20044364L (no) Hydroksykarbamimidoyl-2-hydroksy-benzensulfonamidderivat-krystaller